The Role of Private Equity in Healthcare

Introduction

Private equity's role in healthcare goes far beyond what most candidates expect. In sectors like industrials or consumer, PE is one buyer type among many. In healthcare, PE is often the *primary* buyer. Over 1,029 PE-backed healthcare deals were tracked in the US in 2025 alone, comprising 151 leveraged buyouts, 664 add-on acquisitions, and 214 growth investments across 420 platform companies. Healthcare PE deal value set a record exceeding $190 billion that same year. For healthcare IB analysts, this means that a significant portion of your deal flow will involve PE sponsors as clients, counterparties, or both.

Understanding how PE operates in healthcare is essential for interviews and for day-one effectiveness. The strategic vs. financial buyer distinction introduced in the previous article is the starting framework, but this article goes deeper into PE's specific playbook, the firms that matter, and how IB teams interact with sponsors on a daily basis.

Several structural features make healthcare uniquely attractive to private equity investors, and understanding these features explains why the sector consistently draws more PE capital than its share of GDP would suggest.

Extreme fragmentation. Healthcare services is one of the most fragmented sectors in the US economy. There are over 900,000 physician practices, approximately 200,000 dental practices, and thousands of independent behavioral health providers, home health agencies, and ambulatory surgery centers. Most operate with fewer than 10 providers. This fragmentation is the raw material for the platform and add-on consolidation strategy that drives the majority of healthcare PE deal activity.

Platform Company

The initial acquisition in a PE roll-up strategy, typically a larger, well-managed company that serves as the operational and management infrastructure for subsequent add-on acquisitions. In healthcare, platforms usually have centralized billing, compliance, credentialing, and administrative functions. PE firms typically acquire platforms at 8-12x EBITDA, while individual add-on practices trade at 3-6x.

Recession resistance. Healthcare demand is driven by demographics and medical necessity rather than consumer discretion or economic cycles. People need hip replacements, mental health treatment, and dental care regardless of GDP growth. This non-cyclical demand profile makes healthcare services companies attractive to PE investors who need to underwrite stable cash flows against leveraged capital structures.

Favorable demographics. The US population over 65 is projected to grow from roughly 58 million in 2022 to over 80 million by 2040. This aging demographic drives increasing demand for virtually every healthcare service category, from orthopedic procedures to home health to specialty pharmaceuticals. PE firms can underwrite organic volume growth with high confidence because the demographic tailwind is structural and predictable.

Regulatory barriers to entry. Once a healthcare services platform reaches scale, the regulatory complexity of healthcare (licensure requirements, payer contracting, compliance infrastructure, certificate of need laws) creates a natural moat. New entrants face significant barriers to replication, which protects the platform's competitive position and supports premium exit multiples.

Healthcare PE spans a wide range of firms, from generalist mega-funds with dedicated healthcare teams to specialist firms that invest exclusively in healthcare.

Add-On Acquisition (Bolt-On)

A smaller acquisition made by a PE-backed platform company to expand its geographic footprint, add a new service line, or increase scale. Add-ons are acquired at lower multiples than the platform (typically 3-6x EBITDA vs. 8-12x for the platform) and are integrated into the platform's existing infrastructure. In 2025, add-on acquisitions accounted for 664 of the 1,029 tracked PE healthcare deals, roughly 65% of all activity.

Welsh Carson Anderson & Stowe (WCAS) stands out as the most prominent healthcare-specialist PE firm, having raised over $33 billion in committed capital across its history. WCAS invests exclusively in healthcare and technology, with healthcare portfolio companies spanning services, IT, and pharma services. The firm's operating partner model (bringing in healthcare executives with deep domain expertise to drive post-acquisition value creation) is widely replicated across the industry.

The most active sub-sectors for PE deal flow in 2025 were health IT (151 deals), dental care (149 deals), outpatient care (148 deals), medtech (117 deals), and behavioral health (56 deals). Dental care is particularly illustrative of the roll-up model in action: 95% of dental deals were add-on acquisitions by existing PE-backed platforms, reflecting a market where the consolidation playbook is mature and repeatable.

For healthcare IB analysts, PE sponsors are omnipresent. The interaction takes several forms:

Sell-side mandates. When a PE firm is ready to exit a healthcare services portfolio company (typically after a 3-5 year hold period), it hires a healthcare IB team to run the sale process. The banker prepares the confidential information memorandum (CIM), builds the financial model, manages the data room, and runs a structured auction process targeting both strategic buyers and other PE firms. Healthcare services sell-sides are a bread-and-butter work stream at every healthcare IB group.

Buy-side advisory. PE firms also hire healthcare bankers to advise on platform acquisitions, particularly when the target is a complex healthcare business that requires domain expertise to evaluate. The banker helps the PE firm assess payer mix quality, regulatory risk, provider retention trends, and add-on pipeline opportunity.

Ongoing relationship management. Healthcare coverage bankers maintain relationships with PE firms as aggressively as they do with corporate clients. A senior healthcare banker at a middle-market firm might have regular check-ins with 15-20 healthcare PE firms, discussing deal pipeline, sector trends, and potential mandates. For analysts, this means preparing industry update presentations, running preliminary valuations on potential targets, and supporting pitchbook creation for PE sponsors.